Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis
Tóm tắt
The purpose of this study was to perform a systematic review and meta-analysis of exogenous surfactant administration to assess whether this therapy may be useful in adult patients with acute respiratory distress syndrome. We performed a computerized literature search from 1966 to December 2005 to identify randomized clinical trials. The primary outcome measure was mortality 28–30 days after randomization. Secondary outcome measures included a change in oxygenation (PaO2:FiO2 ratio), the number of ventilation-free days, and the mean duration of ventilation. Meta-analysis was performed using the inverse variance method. Two hundred and fifty-one articles were identified. Five studies met our inclusion criteria. Treatment with pulmonary surfactant was not associated with reduced mortality compared with the control group (odds ratio 0.97; 95% confidence interval (CI) 0.73, 1.30). Subgroup analysis revealed no difference between surfactant containing surface protein or not – the pooled odds ratio for mortality was 0.87 (95% CI 0.48, 1.58) for trials using surface protein and the odds ratio was 1.08 (95% CI 0.72, 1.64) for trials without surface protein. The mean difference in change in the PaO2:FiO2 ratio was not significant (P = 0.11). There was a trend for improved oxygenation in the surfactant group (pooled mean change 13.18 mmHg, standard error 8.23 mmHg; 95% CI -2.95, 29.32). The number of ventilation-free days and the mean duration of ventilation could not undergo pooled analysis due to a lack of sufficient data. Exogenous surfactant may improve oxygenation but has not been shown to improve mortality. Currently, exogenous surfactant cannot be considered an effective adjunctive therapy in acute respiratory distress syndrome.
Tài liệu tham khảo
Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W: Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001, 2: 353-364. 10.1186/rr86
National Heart and Lung Institute: Task force on problems, research approaches, needs: the lung program. Publication No. (NIII) 73-432. Washington, DC: Department of Health, Education, and Welfare; 1972:165-180.
Lewis JF, Veldhuizen R: The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol 2003, 65: 613-642. 10.1146/annurev.physiol.65.092101.142434
Lewis JF, Brackenbury A: Role of exogenous surfactant in acute lung injury. Crit Care Med 2003,31(4 Suppl):S324-S328. 10.1097/01.CCM.0000057911.19145.9F
Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000, 342: 1334-1349. 10.1056/NEJM200005043421806
The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000, 342: 1301-1308. 10.1056/NEJM200005043421801
The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004, 351: 327-336. 10.1056/NEJMoa032193
Frerking I, Gunther A, Seeger W, Pison U: Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 2001, 27: 1699-1717. 10.1007/s00134-001-1121-5
Spragg RG, Lewis J: Surfactant therapy in the acute respiratory distress syndrome. In Acute Respiratory Distress Syndrome. Lung Biology and Health and Disease Series. Volume 179. Edited by: Matthay M. New York: Marcel Dekker Inc; 2003:533-562.
Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay H: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4
Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, et al.: Bronchopulmonary segmental lavage with surfaxin (KL4-Surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999, 160: 1188-1195.
Pallua N, Warbanow K, Noah EM, Machens H-G, Poets C, Bernhard W, Berger A: Intrabronchial surfactant application in cases of inhalation injury: first results from patients with severe burns and ARDS. Burns 1998, 24: 197-206. 10.1016/S0305-4179(97)00112-5
Walmrath D, Günther A, Ghofrani HA, Schermuly R, Schneider T, Grimminger F, Seeger W: Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996, 154: 57-62.
Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, Gunther A, Schmehl T, Leuchte H, Seeger W: Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 2002, 19: 805-810. 10.1183/09031936.02.00243402
Spragg RG, Gilliard N, Richman P, Smith RM, Hite RD, Pappert D, Robertson B, Curstedt T, Strayer D: Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994, 105: 195-202.
Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, Horton J, Pattishall EN: Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994, 272: 1433-1438. 10.1001/jama.272.18.1433
Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli D, Pattishall EN: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996, 334: 1417-1421. 10.1056/NEJM199605303342201
Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, et al.: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997, 155: 1309-1315.
Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ: Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003, 167: 1562-1566. 10.1164/rccm.200207-782OC
Spragg RG, Lewis JF, Walmrath D, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, et al.: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004, 351: 884-892. 10.1056/NEJMoa033181
Gregory TJ, Hite RD, Hicklin G, Reardon C, Kinasewitz G, Heard S, Apostolakos M, Fletcher EC, Tsai H, Schaber CJ: Dose escalation study of surfaxin delivered via bronchopulmonary segmental lavage (BPSL) in patients with ARDS [abstract]. Am J Respir Crit Care Med 2003, 167: A178.
Kesecioglu J, Schultz MJ, Lundberg D, Lauven PM, Lachmann B: Treatment of acute lung injury (ALI/ARDS) with surfactant [abstract]. Am J Respir Crit Care Med 2001, 163: A819.
Spragg RG, Lewis JF, Rathgeb F, Hafner D, Seeger W: Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS [abstract]. Am J Respir Crit Care Med 2002, 165: A22.
Spragg RG, Harris KW, Lewis J, Marsh JJ, Wurst W, Rathgeb F: Surfactant treatment of patients with ARDS may reduce acute lung inflammation [abstract]. Am J Respir Crit Care Med 2001, 163: A23.
Walmrath D, De Vaal JB, Bruining HA, Kilian JG, Papazian L, Hohlfeld J, Vogelmeier C, Wurst W, Schaffer P, Rathgeb F, et al.: Treatment of ARDS with a recombinant SP-C (rSP-C) based synthetic surfactant [abstract]. Am J Respir Crit Care Med 2000, 161: A379.
MacIntyre NR, Coleman RE, Schuller FS, Zaccardelli D, Pattishall E: Efficiency of the delivery of aerosolized artificial surfactant in intubated patients with the adult respiratory distress syndrome [abstract]. Am J Respir Crit Care Med 1994, 149: A125.
Reines HD, Silverman H, Hurst J, Warren J, Williams J, Rotello L, Horton J, Pattishall E: Effects of two concentrations of nebulized surfactant (Exosurf) in sepsis-induced adult respiratory distress syndrome (ARDS) [abstract]. Crit Care Med 1992, 20: S61.
Adhikari N, Burns KEA, Meade MO: Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: systematic review and meta-analysis. Treatments Respir Med 2004, 3: 307-382. 10.2165/00151829-200403050-00005
Frerking I, Gunther A, Seeger W, Pison U: Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 2001, 27: 1699-1717. 10.1007/s00134-001-1121-5
Cranshaw J, Griffiths MJD, Evans TW: The pulmonary physician in critical care: non-ventilatory strategies in ARDS. Thorax 2002, 57: 823-829. 10.1136/thorax.57.9.823
Willson DF, Thomas NJ, Markovitz BP, Pediatric Acute Lung Injury and Sepsis Investigators: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005, 293: 470-476. 10.1001/jama.293.4.470
Derdak S, Mehta S, Stewart TE, Smith T, Rogers M, Buchman TG, Carlin B, Lowson S, Granton J, the Multicenter Oscillatory Ventilation for Acute Respiratory Distress Syndrome Trial (MOAT) Study Investigators: High-frequency oscillatory ventilation for acute respiratory distress syndrome in adults – a randomized, controlled trial. Am J Respir Crit Care Med 2002, 166: 801-808. 10.1164/rccm.2108052
Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, Malacrida R, Di Giulio P, Fumagalli R, Pelosi P, for the Prone–Supine Study Group, et al.: Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001, 345: 568-573. 10.1056/NEJMoa010043
Cordingley JJ, Keogh BF: The pulmonary physician in critical care. 8: ventilatory management of ALI/ARDS. Thorax 2002, 57: 729-734. 10.1136/thorax.57.8.729